Atherosclerotic lesions can result in fatal cardiovascular disease, but what triggers the formation of the atheroma plaques and their progression still begs further investigation. In 'Bench to Bedside', Göran K Hansson and Lars Klareskog peruse how the NLRP3 inflammasome can be activated by cholesterol crystals and worsen atherosclerosis by triggering inflammation through the release of IL-1β from macrophages. But these cells can also die at the lesion site, forming a necrotic core in the atheroma by building up apoptotic cells and debris. In 'Bedside to Bench', Ira Tabas discusses a human study showing that lesional necrosis along with thinning of the fibrotic cap are predictive of culprit lesions involved in fatal disease. Understanding the molecular underpinnings of these two morphological features may lead to new therapies to prevent or decrease the risk for major cardiovascular disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy
Scientific Reports Open Access 03 June 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Martinon, F., Burns, K. & Tschopp, J. Mol. Cell 10, 417–426 (2002).
Agostini, L. et al. Immunity 20, 319–325 (2004).
Dinarello, C.A. J. Intern. Med. 269, 16–28 (2011).
Hawkins, P.N., Lachmann, H.J. & McDermott, M.F. N. Engl. J. Med. 348, 2583–2584 (2003).
Matzinger, P. Annu. Rev. Immunol. 12, 991–1045 (1994).
Shi, Y., Evans, J.E. & Rock, K.L. Nature 425, 516–521 (2003).
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Nature 440, 237–241 (2006).
Chen, C.J. et al. J. Clin. Invest. 116, 2262–2271 (2006).
So, A., De Smedt, T., Revaz, S. & Tschopp, J. Arthritis Res. Ther. 9, R28 (2007).
Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Nat. Immunol. 11, 136–140 (2010).
Larsen, C.M. et al. N. Engl. J. Med. 356, 1517–1526 (2007).
Hansson, G.K. & Hermansson, A. Nat. Immunol. 12, 204–212 (2011).
Duewell, P. et al. Nature 464, 1357–1361 (2010).
Rajamäki, K. et al. PLoS ONE 5, e11765 (2010).
Menu, P. et al. Cell Death Dis. 2, e137 (2011).
Elhage, R. et al. Circulation 97, 242–244 (1998).
Frostegård, J. et al. Atherosclerosis 145, 33–43 (1999).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hansson, G., Klareskog, L. Pulling down the plug on atherosclerosis: Cooling down the inflammasome. Nat Med 17, 790–791 (2011). https://doi.org/10.1038/nm0711-790
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0711-790
This article is cited by
-
Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy
Scientific Reports (2015)
-
Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE−/− mice possibly via activated STAT3-mediated upregulation of tristetraprolin
Acta Pharmacologica Sinica (2013)